Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Ready for the challenge? Let’s begin!
Which combination therapy showed superior progression-free survival compared with osimertinib for EGFR-mutated NSCLC?
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
Read More
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More